Skip to main content
Top
Published in: Clinical and Experimental Medicine 1/2024

Open Access 01-12-2024 | Ascites | Research

Ascites fluid calprotectin level is highly accurate in diagnosing spontaneous bacterial peritonitis: a preliminary proof of concept prospective study

Authors: Wisam Sbeit, Basheer Maamoun, Subhi Azzam, Amir Shahin, Michal Carmiel-Haggai, Tawfik Khoury

Published in: Clinical and Experimental Medicine | Issue 1/2024

Login to get access

Abstract

Ascites is the most common complication of liver cirrhosis. Spontaneous bacterial peritonitis (SBP) is a common complication of ascites. The diagnosis is made by an ascitic fluid polymorphonuclear (PMN) cell count of ≥ 250/mm3. However, no other diagnostic test is present for the diagnosis of SBP. The aim of the study present study is to assess the diagnostic yield of ascitic calprotectin in SBP, and to explore whether it can predict disease stage. We performed a single center proof-of-concept prospective study including all patients with cirrhosis and ascites who underwent paracentesis. Overall, 31 patients were included in the study. Eight patients had SBP vs. 23 patients without SBP. Ascitic calprotectin level was 77.4 ± 86.5 μg/mL in the SBP group, as compared to 16.1 ± 5.6 μg/mL in the non-SBP group (P = 0.001). An ascitic calprotectin cut-off value of > 21 μg/mL was associated with sensitivity and specificity of 85.7% and 89.5%, respectively, with ROC of 0.947 (95% CI 0.783 to 0.997, P < 0.0001). Notably, ascitic calprotectin did not had a prognostic value in cirrhosis stage and prognosis. Ascitic calprotectin was highly accurate in the diagnosis of SBP. It can be a serve as adjunct for indefinite cases of SBP.
Literature
1.
go back to reference Gines P, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7(1):122–8.CrossRefPubMed Gines P, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7(1):122–8.CrossRefPubMed
2.
go back to reference Runyon BA, Aasld,. Introduction to the revised American association for the study of liver diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651–3.CrossRefPubMed Runyon BA, Aasld,. Introduction to the revised American association for the study of liver diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651–3.CrossRefPubMed
3.
4.
go back to reference Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2017;13(1):53–6.PubMed Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2017;13(1):53–6.PubMed
5.
go back to reference Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 1980;16(Suppl):273–82.PubMed Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 1980;16(Suppl):273–82.PubMed
6.
go back to reference Poullis A, et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003;18(7):756–62.CrossRefPubMed Poullis A, et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003;18(7):756–62.CrossRefPubMed
7.
go back to reference Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34(1):50–4.CrossRefPubMed Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34(1):50–4.CrossRefPubMed
8.
go back to reference Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc). 2001;37(2):85–96.CrossRefPubMed Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc). 2001;37(2):85–96.CrossRefPubMed
9.
go back to reference Honar N, et al. An evaluation of ascitic calprotectin for diagnosis of ascitic fluid infection in children with cirrhosis. BMC Pediatr. 2022;22(1):382.CrossRefPubMedPubMedCentral Honar N, et al. An evaluation of ascitic calprotectin for diagnosis of ascitic fluid infection in children with cirrhosis. BMC Pediatr. 2022;22(1):382.CrossRefPubMedPubMedCentral
10.
go back to reference Nasereslami M, et al. Diagnostic and prognostic role of ascitic fluid calprotectin level: six-month outcome findings in cirrhotic patients. Scand J Gastroenterol. 2020;55(9):1093–8.CrossRefPubMed Nasereslami M, et al. Diagnostic and prognostic role of ascitic fluid calprotectin level: six-month outcome findings in cirrhotic patients. Scand J Gastroenterol. 2020;55(9):1093–8.CrossRefPubMed
12.
go back to reference Hadjivasilis A, et al. The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2021;33(3):312–8.CrossRefPubMed Hadjivasilis A, et al. The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2021;33(3):312–8.CrossRefPubMed
13.
go back to reference Burri E, et al. Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count. World J Gastroenterol. 2013;19(13):2028–36.CrossRefPubMedPubMedCentral Burri E, et al. Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count. World J Gastroenterol. 2013;19(13):2028–36.CrossRefPubMedPubMedCentral
14.
go back to reference Lutz P, et al. The ratio of calprotectin to total protein as a diagnostic and prognostic marker for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. Clin Chem Lab Med. 2015;53(12):2031–9.CrossRefPubMed Lutz P, et al. The ratio of calprotectin to total protein as a diagnostic and prognostic marker for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. Clin Chem Lab Med. 2015;53(12):2031–9.CrossRefPubMed
15.
go back to reference Abdel-Razik A, et al. Ascitic fluid calprotectin and serum procalcitonin as accurate diagnostic markers for spontaneous bacterial peritonitis. Gut Liver. 2016;10(4):624–31.CrossRefPubMed Abdel-Razik A, et al. Ascitic fluid calprotectin and serum procalcitonin as accurate diagnostic markers for spontaneous bacterial peritonitis. Gut Liver. 2016;10(4):624–31.CrossRefPubMed
16.
go back to reference Nabiel Y, Barakat G, Abed S. Serum CD64 and ascitic fluid calprotectin and microRNA-155 as potential biomarkers of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2019;31(8):1064–9.CrossRefPubMed Nabiel Y, Barakat G, Abed S. Serum CD64 and ascitic fluid calprotectin and microRNA-155 as potential biomarkers of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2019;31(8):1064–9.CrossRefPubMed
17.
18.
go back to reference Weil D, et al. Accuracy of calprotectin using the quantum blue reader for the diagnosis of spontaneous bacterial peritonitis in liver cirrhosis. Hepatol Res. 2019;49(1):72–81.CrossRefPubMed Weil D, et al. Accuracy of calprotectin using the quantum blue reader for the diagnosis of spontaneous bacterial peritonitis in liver cirrhosis. Hepatol Res. 2019;49(1):72–81.CrossRefPubMed
19.
go back to reference Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8(2):197–210.CrossRefPubMed Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8(2):197–210.CrossRefPubMed
21.
Metadata
Title
Ascites fluid calprotectin level is highly accurate in diagnosing spontaneous bacterial peritonitis: a preliminary proof of concept prospective study
Authors
Wisam Sbeit
Basheer Maamoun
Subhi Azzam
Amir Shahin
Michal Carmiel-Haggai
Tawfik Khoury
Publication date
01-12-2024
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 1/2024
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-023-01257-0

Other articles of this Issue 1/2024

Clinical and Experimental Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.